Deepak Cyril D’Souza

Author

Also Known As

D C D'Souza, D Cyril D'Souza, D D'Souza, D'Souza, Deepak, D. C. D'Souza, D. CYRIL D'SOUZA, D. Cyril D'Souza, D. Cyril D'souza, D. Cyril D’Souza, D. D'Souza

245

Publications

13.2K

Citations

H-Index

117

Concepts

All Affiliations

Yale University VA Connecticut Healthcare System Connecticut Mental Health Center Columbia University Nathan Kline Institute for Psychiatric Research

About

Deepak Cyril D’Souza is an author at Yale University specializing in medicine, social sciences, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	63	6.5K
2	Social Sciences	35	51	5.6K
3	Health Sciences	8	8	703
4	Engineering	3	3	193
5	Public Health	1	1	23

Deepak Cyril D’Souza

Publications

8.4K

Citations

H-Index

Page 1

	Year	Citations
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis Deepak Cyril D’Souza, Edward Perry, Lisa Macdougall, Neuropsychopharmacology Cannabis UseSubstance AbuseHealthy IndividualsPsychoactive DrugPsychiatry	2004	1K
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction Deepak Cyril D’Souza, Walid Abi‐Saab, Steven Madonick, Biological Psychiatry Cannabis UseDelta-9-tetrahydrocannabinol EffectsSubstance AbusePsychoactive DrugPsychopathology	2005	604
Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia Mark Slifstein, Elsmarieke van de Giessen, Jared X. Van Snellenberg, JAMA Psychiatry	2015	386
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects John H. Krystal, Walid Abi‐Saab, Edward Perry, Psychopharmacology PsychiatryBrain FunctionMedicineDisruptive EffectsPsychopharmacology	2004	272
Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis Deepak Cyril D’Souza, Mohini Ranganathan, Gabriel Braley, Neuropsychopharmacology Cannabis UsePsychoactive DrugPsychiatryAmnestic EffectsAddiction	2008	258
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans John Krystal, Deepak Cyril D’Souza, Laurence P. Karper, Psychopharmacology NeurophysiologyMedicineAnesthetic MechanismNeuropharmacologyPharmacotherapy	1999	243
Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans Naomi Driesen, Gregory McCarthy, Zubin Bhagwagar, Molecular Psychiatry NeuropsychologyPsychiatryNeurophysiologyBrain HyperconnectivityPsychotropic Medication	2013	231
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial Douglas L. Boggs, Toral Surti, Aarti Gupta, Psychopharmacology Cannabis UsePsychopathologyPsychiatryPsychotic DisorderAddiction	2018	224
Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis Deepak Cyril D’Souza, Jose Cortes-Briones, Mohini Ranganathan, Biological Psychiatry Cognitive Neuroscience and Neuroimaging Cannabis UseSubstance AbuseHealth SciencesCannabinoid 1Receptor Availability	2015	204
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial Deepak Cyril D’Souza, Jose Cortes-Briones, Gina Creatura, The Lancet Psychiatry Cannabis UseSubstance AbuseSubstance UseHealth SciencesPsychiatry	2018	183

Page 1